Abstract 5661
Background
Chemotherapy (CT) plays a vital role as conversion treatment for initially unresectable or borderline resectable colorectal cancer (CRC). Targeted therapies are recommended with CT for conversion therapy; however, their role in conversion of initially unresectable tumours has not been elucidated. This meta-analysis evaluated the role of targeted therapies for conversion aimed at R0 resection in KRAS WT mCRC.
Methods
We conducted a literature search for randomized controlled trials (RCTs) in PubMed, Embase and Cochrane library evaluating the role of anti EGFR and anti VEGF as conversion therapies. A comparison was performed for anti-EGFR + CT vs. anti-VEGF + CT (Gp. A) and anti-EGFR + CT vs. CT (Gp. B). R0 resection rate and objective response rate (ORR) were the primary outcomes; with overall survival (OS), progression free survival (PFS) and safety evaluated as the secondary outcomes. Primary outcomes and safety were presented as relative risk (RR) and 95% confidence interval (CI), whereas survival was presented as hazard ratio (HR) and 95%CI.
Results
We identified 8 RCTs from the potential 81 studies. In Gp. A, a fixed effects model was used for analysis; and showed that although non-significant, anti EGFR + CT had better R0 resection rate (RR 1.44, 95% CI 0.91,2.27; p = 0.1156; I2 = 0%) and ORR (RR 1.05, 95% CI 0.88, 1.24; p = 0.6039; I2 = 0%) compared with anti VEGF + CT. OS with anti EGFR + CT was significantly longer than anti VEGF + CT (HR: 0.64; CI 0.47, 0.86; p = 0.0036; I2 = 0%); however, PFS was numerically better in anti EGFR + CT. Compared with CT alone, anti EGFR + CT resulted in significantly higher R0 resection rate (RR 1.85, 95% CI 1.15,2.98; p = 0.0107; I2 = 57.16%) and ORR (RR 1.19, 95% CI 1.11, 1.28; p < 0.0001; I2 = 0%). In Gp. B, only PFS was significantly longer with anti EGFR + CT vs. CT (HR: 0.85; 95% CI 0.74, 0.98; p = 0.0015; I2 = 45.60%), and not OS. Safety evaluation showed anti EGFR + CT with significantly greater adverse events than CT alone (RR: 1.26; 95% CI: 1.18, 1.35; p < 0.0001).
Conclusions
In conclusion, anti EGFR + CT was an effective conversion therapy compared with anti VEGF + CT and CT in patients with initially unresectable mCRC; however, frequency of AEs was more with targeted therapy.
Clinical trial identification
Legal entity responsible for the study
Merck Serono Co. Ltd.
Funding
Merck Serono Co. Ltd.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4162 - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
Presenter: Anu Moilanen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3747 - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
Presenter: Roman Dubianski
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4688 - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.
Presenter: Pietro Paolo Vitiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
498 - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Presenter: Xiao Fu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3731 - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1215 - Cisplatin in NIPEC or HIPEC?
Presenter: Ivan Alvovsky
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2738 - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
Presenter: MARIKO HIRAI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2190 - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
Presenter: Priya Sriskandarajah
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor
Presenter: Davide Ciardiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
624 - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
Presenter: Hugo Arasanz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract